Medifast Reports Steep Q1 Revenue Decline, Increased Losses, and Negative 2026 Outlook Amid Industry Headwinds

summarizeSummary

Medifast announced a significant 34.3% year-over-year revenue decrease and an expanded net loss for Q1 2026, alongside negative guidance for Q2 and the full year, reflecting ongoing challenges from GLP-1 medications.

check_boxKey Events

• Q1 2026 Financial Results

  Revenue decreased 34.3% year-over-year to $76.0 million. The company reported a net loss of $2.1 million, or $0.19 per diluted share, compared to a net loss of $0.8 million ($0.07 EPS) in Q1 2025.

• Declining Coach Network

  The total number of active earning coaches decreased 44.9% to 14,000 compared to Q1 2025, with expectations for further declines in 2026 due to client acquisition challenges and GLP-1 medication adoption.

• Q2 2026 Guidance Issued

  The company projects Q2 2026 revenue to be in the range of $60 million to $80 million and a loss per share between $0.50 and $1.00.

• Full Year 2026 Outlook

  Medifast forecasts full year 2026 revenue between $270 million and $300 million, with an anticipated loss per share ranging from $1.55 to $2.75.

auto_awesomeAnalysis

This 8-K confirms Medifast's continued struggle with declining sales and profitability, primarily due to a shrinking coach network and competitive pressure from GLP-1 weight loss drugs. The substantial year-over-year revenue drop and increased net loss in Q1, coupled with a forecast for continued losses throughout 2026, indicate that the company's strategic pivot to metabolic health has yet to reverse the negative trend. While coach productivity per active coach improved, the overall number of coaches continues to decline significantly, impacting top-line growth. Investors should monitor the effectiveness of the metabolic health strategy and any signs of stabilization in the coach network and client acquisition.